Floatz logo

Entinostat

Estrogen-Receptor Negative Breast Cancer

University of Maryland, BaltimoreSmall moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Estrogen-Receptor Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Northwestern University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Washington
Phase 3BB
Pembrolizumab
Massachusetts General Hospital
Phase 2BB
Epirubicin
Massachusetts General Hospital
Phase 2BB
Cyclophosphamide
Massachusetts General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Entinostat is also rated in:

Stage IIIA Non-Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →